Inhibition of Arenaviridae nucleoprotein exonuclease by bisphosphonate.

ABSTRACT: Arenaviruses are emerging enveloped negative-sense RNA viruses that cause neurological and hemorrhagic diseases in humans. Currently, no FDA-approved vaccine or therapeutic agent is available except for ribavirin, which must be administered early during infection for optimum efficacy. A hallmark of arenavirus infection is rapid and efficient immune suppression mediated by the exonuclease domain encoded by the nucleoprotein. This exonuclease is therefore an attractive target for the design of novel antiviral drugs since exonuclease inhibitors might not only have a direct effect on the enzyme but could also boost viral clearance through stimulation of the innate immune system of the host cell. Here, in silico screening and an enzymatic assay were used to identify a novel, specific but

SUBMITTER: Nguyen THV 

PROVIDER: S-EPMC9252148 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature